Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
FPD 31st October 2022
November - December = 8 weeks scan
Feb 21st 23 RNS update
I wouldn't have expected an RNS at the end of December or mid Jan so Feb 21st seems reasonable. Also end of Feb update would be very close to the second scan (16 weeks). So does that mean we might expect to hear the next update close to the third scan (24 weeks) which points to around April?
On the other hand we may get an interim update or non at all.
Thoughts please.
Johnny,
I think it best to email Scancell and pose the question as things may have changed since RNS?
I have emailed them at 9am regarding something else but still waiting for a response.
GF,
With respect. RR has been asking pertinent questions, which by the way people should feel free to answer. These answers will be scrutinsed by members here and debated. People will make their own minds up! I think there are clearly people frequenting this board that are here to cause disruption, manipulate the share price and misrepresent anything they can, yourself and Ruck Rover are NOT among them.
I am with Ruck,
We need to delineate what is stable. We will hopefully see mention of this (or better) many times to come with Modi and SCIB updates. If nobody emails investor relations I will.
I have another question: Is tumor status different in each cancer type or specific to each patient. If it were cancer type it may explain why we see so many with stable disease?
Is it fair to say the conversation is about twenty three patients now, not just one?
Just saying: maybe TM deserves a break with all she has and is dealing with. Lots to occupy our minds otherwise. I mean it is likely that there will be a range of clinical reactions that are completely different. Even though this could be a pan cancer vaccine one day.
Thanks Burble,
So delayed regression is possible or at least was in the case you highlighted.
Q. As it appears delayed regression could be a possibility with Modi - 1 also, if you were part of the Scancell team, would you have factored this in as an expected possibility before stating the trial. In other words is it known to happen commonly?
ATB
As I understand it, CI's are not appropriate for all patients. For this reason I am especially keen to see the ovarian side of the study. It is not only what Moditope can do in combination with CI, but on its own. CI can cause adverse effects and be of little use in some cases.
Please correct me if I am wrong.
Violin Dog,
The share price rises and falls. Becoming concerned is not advisable as there really is nothing we can do about it. It is a bit like being on a roller coaster; the ups and downs cant harm you so why not sit back and relax? I can assure you, everything that is going to happen with the stock WILL happen, regardless of whether i scream and shout, panic, get angry, whinge or whine...
My voice (along with everyone else's on these bulletin board's) is all but a blue bottle hitting the windscreen at 70mph on the epic Scancell journey!
ATB
Regarding those mice... (sorry to the subject up again)
"The effect is caused by key unique sequence residues that are present in the mouse but not seen in the equivalent human antibodies. Essentially AvidiMab can transfer these active residues to any target humanised antibody and so enhance non-covalent interactions between any mAb (or similarly structured) molecules resulting in a material improvement in avidity and potency."
This is an exert from the TD note. Have we all read the entire document? If not why not!